Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Behrens–Fisher Test00:57

Behrens–Fisher Test

The Behrens-Fisher test is a statistical method designed to address the Behrens-Fisher problem, which arises when comparing the means of two normally distributed populations with unequal variances. Unlike the Student's t-test, which assumes equal variances, the Behrens-Fisher test allows for mean comparison without this restrictive assumption. This flexibility makes it particularly valuable in scenarios where two independent samples exhibit normality but lack variance homogeneity.
This test is...
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>HK2</i> knockdown is associated with context-dependent inflammatory and angiogenesis-related transcriptional programmes in glioblastoma cells.

Frontiers in immunology·2026
Same author

Language models do not yet achieve explanatory adequacy because language is more than incremental prediction.

The Behavioral and brain sciences·2026
Same author

Children's narrow learning bottleneck accelerates the emergence of statistical properties of language.

Cognition·2026
Same author

Using objective measures of physical activity, sleep, and breathing for disease profiling of patients with systemic lupus erythematosus and Sjögren's disease.

Frontiers in digital health·2026
Same author

Neurocognitive Aging Following Acute Illness: Pathobiology and a Framework for Developing Neurotherapeutic Agents.

Brain and behavior·2026
Same author

Cultural Transmission Promotes the Emergence of Statistical Properties That Support Language Learning.

Cognitive science·2025

Related Experiment Video

Updated: Jun 10, 2026

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

Determining a minimum clinically important difference between treatments for a patient-reported outcome.

Simon Kirby1, Christy Chuang-Stein, Mark Morris

  • 1Statistics, Pfizer Limited, Sandwich, United Kingdom. simon.kirby@pfizer.com

Journal of Biopharmaceutical Statistics
|August 20, 2010
PubMed
Summary

This study introduces a novel method to determine the minimum clinically important difference for patient-reported outcomes, enhancing treatment assessment and potentially reducing sample sizes in clinical trials.

More Related Videos

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

Related Experiment Videos

Last Updated: Jun 10, 2026

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

Area of Science:

  • Clinical research methodology
  • Patient-reported outcomes
  • Statistical analysis in healthcare

Background:

  • Patient-reported outcomes (PROs) are crucial for evaluating treatment efficacy across various medical conditions.
  • The development of new PRO instruments necessitates methods to define minimum clinically important differences (MCIDs).
  • Establishing MCIDs is essential for interpreting the clinical significance of treatment effects observed in PRO data.

Purpose of the Study:

  • To present a method for estimating the MCID for PROs based on a desired difference in responder rates.
  • To demonstrate how this MCID estimation can inform sample size calculations for clinical trials.
  • To apply the proposed method using data from neuropathic pain studies.

Main Methods:

  • The study describes a statistical approach to link MCID on a PRO scale to a predefined difference in the proportion of responders.
  • Responder status is defined using criteria such as improvement in Patient Global Impression of Change (PGIC) or established responder definitions.
  • The method is illustrated with empirical data to show its practical application.

Main Results:

  • The proposed method provides a framework for quantifying the MCID in terms of responder rates.
  • Utilizing MCID derived from responder definitions can lead to sample size advantages in clinical trials.
  • The application to neuropathic pain data demonstrates the feasibility of the approach.

Conclusions:

  • The developed method offers a robust way to estimate MCID for PROs, directly linking it to clinically meaningful response.
  • This approach aids in the interpretation of PRO data and can optimize clinical trial design by potentially reducing required sample sizes.
  • The findings are applicable to various disease areas utilizing PRO measures for treatment evaluation.